|Anthera Pharmaceuticals, Inc.|
25801 Industrial Boulevard
United States - Map
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing products to treat diseases associated with inflammation and autoimmune diseases. The companys primary product candidate is blisibimod, which is in Phase III clinical trials targeting elevated levels of B-cell activating factor (BAFF) associated with various B-cell mediated autoimmune diseases, including systemic lupus erythematosus, IgA nephropathy, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others. It has a license agreement with Amgen Inc. to develop and commercialize BAFF inhibitor blisibimod, as well as non-exclusive rights to certain technology relating to peptibody compositions and formulations. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.
|Mr. Paul F. Truex MBA,
Chief Exec. Officer, Pres and Director
|Dr. Debra Odink Ph.D.,
Chief Technology Officer and Sr. VP
|Dr. Colin Hislop M.D.,
Chief Medical Officer and Sr. VP
|Ms. May Liu ,
Principal Accounting Officer and Sr. VP of Fin. & Admin.
|Dr. Paul Adams Ph.D.,
VP of Regulatory Affairs & Compliance
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|